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It is know that thrombocytopoietin is a specific humoral thrombocy top oie sis regulator (8). 
It is supposed that it presents a glucoproteide (4) and it is synthesized in kidney (9). Concern­
ing its place and mechanism of action it is known that it stimulates the development of com­
mitted precursors of megakaryocytes and of megakaryocytes themselves as well (7, 12). There 
are single investigations of plasma thrombocytopoietin activity (РТА) in healthy persons and 
patients with different blood diseases (1 ,5) . 
The aim of the present study is to follow-up РТА in patients with changed thrombocyte 
count. 
Material and Methods 
We determined РТА in 22 females of which 10 healthy controls and 12 patients with the fol­
lowing diseases: 3 — with idiopathic thrombocytopenic purpura (ITP), 8 - with symptomatic 
thrombocytopenia (ST) and one with essential thrombocytemia ( E T ) . Plasma was injected to a 
total of 112 male mice (72 experimental and 40 control). РТА level was evaluated according to 
changes of 7 5 selenomethionine ( 7 5 Se-M) incorporation in newly-formed thrombocytes a^well 
as to thrombocyte count in peripheral blood of recipient mice. The percentage of the incorpo­
rated 7 5 Se-M was determined after widely used radioisotope Penington's method (10) in our 
modification. To this purpose we used as recipients instead of C57-non-thoroughbred white 
male mice only mice with initial thrombocyte count between 200 and 380.10 9/1. Plasma was 
injected subcutaneously at dosis 1 ml on two consecutive days. All the mice were intraperio-
neally injected 2 Ci 7 5 Se-M each one hour after the second injection. 72 hours after mat we as­
pirated by means of cardiac puncture 0.5 ml blood from all the mice each under ether narcosis 
in order to determine the percentage of isotope incorporated. We apprehended to determine 
7 5 Se-M incorporation instead on the 24th hour (as proposed by Penington) on the 72nd 0ne be­
cause this period coincided with the peak of thrombocyte count increase and most manifested 
changes of isotope incorporation as well. Further sample processing and calculation o f 7 5 Se-M 
incorporation into thrombocytes was carried out completely after Penington's method. 
Initial thrombocyte levels were determined with all the mice at the end of experiment after 
Feissly and Ludin (cited after 3), too. 
All the animals were divided into 4 groups, namely: 1st group - injected with plasma from 
ITP patients; 2nd _ with plasma from ST ones; 3rd _ with plasma from E T patients, and 4th _ 
with plasma from healthy individuals (controls). 
Data obtained were processed by the methods of variation analysis. 
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Results and Discussion 
On fig. 1 and 2 one can see the data about РТА determined by the percentage of 7 5Se-M 
incorporated in newly-formed thrombocytes as well as thrombocyte count changes. It has to 
be noted that plasma from ITP and ST patients does not cause one and the same kind of chan­
ges in the parameters studied in all the patients of one and the same group. More concretely, 
plasma of one female ITP patient causes a strong isotope incorporation increase (with 46.37 per 
cent, p < 0.025) and thrombocyte count one (with 32.96 per cent, p < 0.05) although there is 
a normal thrombocyte count in this patient. However, plasma injection from the* rest two pa­
tients of this group reduces 7 5 Se-M incorporation with 73.41 per cent (p < 0.001) and throm­
bocyte count with 42.50 per cent (p < 0.001) in recipient mice. Thrombocyte number is below 
80.10 9/! in both patients. 
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Fip 1. РТА determined by the percentage of -Se-M incorporated in newly-formed thrombocytes of reci­
pient mouse. Percentage deviation is determined in relation to the control level accepted for "0". Sign (+) 
indicates an increase and sign ( - ) a decrease. 
ST patients show also contrary' results. Plasma induces isotope incorporation increase in 
62.50 per cent of them with 37.14 per cent (p < 0.001) and thrombocyte count one with 
45.26 per cent (p < 0.001). There is a considerable reduction in the rest patients (36.50 per 
cent) of 7 5 Se-M incorporation (with 34.94 per cent, p < 0.025) and of thrombocyte count 
(with 41.C9 per cent, p < 0.001) as well. The mean thrombocyte number of the patients of the 
whole group is below 50.10 9/1. 
Thrombocytemic plasma injection is followed by 7 5 Se-M incorporation increase in newly 
formed thrombocytes of recipient mice with 34.28 per cent (p < 0.05) and by thrombocyte 
count one with 35.66 per cent (p < 0.025). Patient's thrombocyte number is between 700 and 
1000.109/1. 
In our opinion, increased РТА of some ITP patients and ST ones results from a realized ne­
gative feed-back mechanism induced by their thrombocytopenia (2). Besides we accept that 
strongly reduced РТА of the rest patients with the same diseases provides an indirect evidence 
for probably increased plasma inhibitory properties. This fact coincides with data reported by 
Plasma thrombocytopoietin. 59 
other authors (1 ,6 ) . It can not be excluded mat in this case reduced РТА is due to insufficient 
thrombocytopoietin production. 
- Our data concerning РТА increase in E T cases could be explained to a certain extent by the 
present evidences for an increased thrombocytopoietin activity in chronic myeloid leukemia 
and in other diseases as well (11). According to our opinion, that is confirmation of the idea 
that production of specific humoral thrombocytopoiesis regulator is not regulated only by cir­
culating thrombocyte number but also by bone-marrow megakaryocyte count and other fac­
tors as well (2). 
Having in mind that 7 5 Se-M incorporation and thrombocyte count are basic indexes for РТА 
determination ( 1 , 12) our results obtained allow us to draw the following conclusions: 





























Fig. 2. РТА determined by thrombocyte count changes of recipient mouse. Values are presented as percent­
age deviation in relation to the control level accepted for "0". Sign (+) indicates an increase and sign ( - ) a 
decrease. 
2. These contrary changes of thrombocytopoietin activity allow the suggestion that patho­
genetic mechanisms different to a great extent are involved in these diseases. 
We consider РТА determination a possible additional differential-diagnostic criterion at this 
stage, mainly when patients with E T and to a lower extent when ST patient are concerned. 
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ТРОМБОЦИТОПОЭ.ТИНОВАЯ АКТИВНОСТЬ ПЛАЗМЫ 
У БОЛЬНЫХ С ИЗМЕНЕНИЕМ ЧИСЛА ТРОМБОЦИТОВ 
//. Нее рев, Р. Мишкова, Т. Ганчев 
Р Ь З Ю М Е 
Исследована тромбоцитопоэтиновая активность плазмы у больных с изменением числа тромбо­
цитов по модифицированному авторами радиоизотопному методу Penington (1970). Тромбоцито­
поэтиновая активность плазмы устанавливалась посредством 'процента включенного 75 селено-
метионина в новообразованные тромбоциты и при учете числа тромбоцитов у тест-мышей под влия­
нием испытуемой плазмТл. При зссенциальной тромбоцитемии устанавливается значимое повыше­
ние тромбоцитопоэтиновой активности. У некоторых из больных с идеопатической тромбоцито-
пенической пурпурой и симптоматической тромбоцитопенией устанавливается достоверное увели­
чение тромбоцитопоэтиновой активности плазмы, а у'остальных достоверное уменьшение. Воз­
можно использование этою показателя в качестве дополнительного дифференциально-диагностиче­
ского критерия. 
